| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| mm-141 | erbb3 tyrosine kinase receptor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of pancreas[MeSHID:D010190] Pancreatic carcinoma[MeSHID:C562463] |
1.41 | phase 2 | unknown |
| mm-141 | insulin-like growth factor i receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of pancreas[MeSHID:D010190] Pancreatic carcinoma[MeSHID:C562463] |
1.12 | phase 2 | unknown |
| mm-141 | serine/threonine-protein kinase mtor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of pancreas[MeSHID:D010190] Pancreatic carcinoma[MeSHID:C562463] |
0.16 | phase 2 | unknown |
| click here to return to the previous page | ||||||||